利培酮联合氟西汀对焦虑抑郁共病患者的治疗观察 |
| |
引用本文: | 钱建军 何炳福 石永扬 高赛男 金海龙. 利培酮联合氟西汀对焦虑抑郁共病患者的治疗观察[J]. 中国药物与临床, 2007, 7(9): 680-681 |
| |
作者姓名: | 钱建军 何炳福 石永扬 高赛男 金海龙 |
| |
作者单位: | 浙江省绍兴市第七人民医院心理科,浙江省绍兴市第七人民医院心理科,浙江省绍兴市第七人民医院心理科,浙江省绍兴市第七人民医院心理科,浙江省绍兴市第七人民医院心理科 |
| |
基金项目: | 浙江省绍兴市科技局基金资助项目(2005193) |
| |
摘 要: | 目的观察利培酮联合氟西汀对焦虑抑郁共病的疗效和安全性。方法71例焦虑抑郁共病患者随机分为研究组(利培酮+氟西汀)38例、对照组(氟西汀)33例,治疗8周。于治疗前、治疗后每2周测评汉密尔顿抑郁量表(HAMD)24项、汉密尔顿焦虑量表(HAMA)、治疗中需处理的不良反应量表(TESS)。疗效评价以HAMD减分率为标准,不良反应以TESS评分为标准。结果两组HAMD、HAMA评分组间比较从第2周末开始差异有统计学意义(P<0.05、P<0.01),两组疗效比较差异有统计学意义(P<0.05),各时期TESS评分比较差异无统计学意义(P>0.05)。结论利培酮联合氟西汀治疗焦虑抑郁共病的疗效和安全性较好。
|
关 键 词: | 抑郁症 焦虑症 利培酮 氟西汀 |
修稿时间: | 2007-05-21 |
Risperidone combined with Fiuoxetine in treatment of depression and anxiety comorbidity |
| |
Abstract: | Objective To observe the efficacy and safety of Risperidone combined with Fluoxetine in treatment of depression and anxiety comorbidity. Methods Seventy-one patients with depression and anxiety comorbidity were randomly divided into the study group (risperidone fluoxetine, n=38) and control group (fluoxetine, n=33) to receive therapy as designed for 8 weeks. All patients were assessed with HAMD-24, HAMA and TESS before and every two weeks after initiation of treatment. Results Significant differences in HAMD and HAMA were observed between the two groups starting from week 2 (P<0.05 and P<0.01, respectively), but not in TESS for all times (P>0.05). Conclusion Risperidone combined with fluoxetine showed better efficacy and safety in treatment of depression and anxiety comorbidity. |
| |
Keywords: | Depressive disorder Anxiety disorder Risperidone Fluoxetine |
本文献已被 CNKI 维普 等数据库收录! |